Literature DB >> 7573037

Molecular characterization of minor gene rearrangements in Finnish patients with heterozygous familial hypercholesterolemia: identification of two common missense mutations (Gly823-->Asp and Leu380-->His) and eight rare mutations of the LDL receptor gene.

U M Koivisto1, J S Viikari, K Kontula.   

Abstract

Two deletions of the low-density lipoprotein (LDL) receptor gene were previously shown to account for about two thirds of all mutations causing familial hypercholesterolemia (FH) in Finland. We screened the DNA samples from a cohort representing the remaining 30% of Finnish heterozygous FH patients by amplifying all the 18 exons of the receptor gene by PCR and searching for DNA variations with the SSCP technique. Ten novel mutations were identified, comprising two nonsense and seven missense mutations as well as one frameshift mutation caused by a 13-bp deletion. A single nucleotide change, substituting adenine for guanidine at position 2533 and resulting in an amino acid change of glycine to aspartic acid at codon 823, was found in DNA samples from 14 unrelated FH probands. This mutation (FH-Turku) affects the sequence encoding the putative basolateral sorting signal of the LDL receptor protein; however, the exact functional consequences of this mutation are yet to be examined. The FH-Turku gene and another point mutation (Leu380-->His or FH-Pori) together account for approximately 8% of the FH-causing genes in Finland and are particularly common among FH patients from the southwestern part of the country (combined, 30%). Primer-introduced restriction analysis was applied for convenient assay of the FH-Turku and FH-Pori point mutations. In conclusion, this paper demonstrates the unique genetic background of FH in Finland and describes a commonly occurring FH gene with a missense mutation closest to the C terminus thus far reported.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573037      PMCID: PMC1801494     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  30 in total

1.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

2.  Common low-density lipoprotein receptor mutations in the French Canadian population.

Authors:  E Leitersdorf; E J Tobin; J Davignon; H H Hobbs
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

3.  Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia.

Authors:  H H Hobbs; M S Brown; D W Russell; J Davignon; J L Goldstein
Journal:  N Engl J Med       Date:  1987-09-17       Impact factor: 91.245

Review 4.  Hereditary diseases in Finland; rare flora in rare soul.

Authors:  R Norio; H R Nevanlinna; J Perheentupa
Journal:  Ann Clin Res       Date:  1973-06

5.  European workshop on LDL receptor defects. European Working Group on Familial Hypercholesterolaemia.

Authors:  H Schuster; S Humphries
Journal:  Clin Investig       Date:  1994-11

6.  The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum.

Authors:  M A Lehrman; W J Schneider; M S Brown; C G Davis; A Elhammer; D W Russell; J L Goldstein
Journal:  J Biol Chem       Date:  1987-01-05       Impact factor: 5.157

7.  Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolemia in Afrikaners.

Authors:  E Leitersdorf; D R Van der Westhuyzen; G A Coetzee; H H Hobbs
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

8.  The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA.

Authors:  T Yamamoto; C G Davis; M S Brown; W J Schneider; M L Casey; J L Goldstein; D W Russell
Journal:  Cell       Date:  1984-11       Impact factor: 41.582

9.  A single-base substitution in the proximal Sp1 site of the human low density lipoprotein receptor promoter as a cause of heterozygous familial hypercholesterolemia.

Authors:  U M Koivisto; J J Palvimo; O A Jänne; K Kontula
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

10.  Finnish type of low density lipoprotein receptor gene mutation (FH-Helsinki) deletes exons encoding the carboxy-terminal part of the receptor and creates an internalization-defective phenotype.

Authors:  K Aalto-Setälä; E Helve; P T Kovanen; K Kontula
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

View more
  5 in total

1.  Role of an intramolecular contact on lipoprotein uptake by the LDL receptor.

Authors:  Zhenze Zhao; Peter Michaely
Journal:  Biochim Biophys Acta       Date:  2011-04-09

Review 2.  Hepatocyte polarity.

Authors:  Aleksandr Treyer; Anne Müsch
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

3.  Software and database for the analysis of mutations in the human LDL receptor gene.

Authors:  M Varret; J P Rabès; G Collod-Béroud; C Junien; C Boileau; C Béroud
Journal:  Nucleic Acids Res       Date:  1997-01-01       Impact factor: 16.971

4.  Identification of novel variants in the LDLR gene in Russian patients with familial hypercholesterolemia using targeted sequencing.

Authors:  Valentina V Miroshnikova; Olga V Romanova; Olga N Ivanova; Mikhail A Fedyakov; Alexandra A Panteleeva; Yury A Barbitoff; Maria V Muzalevskaya; Sorejya A Urazgildeeva; Victor S Gurevich; Stanislav P Urazov; Sergey G Scherbak; Andrey M Sarana; Natalia A Semenova; Inga V Anisimova; Darya M Guseva; Sofya N Pchelina; Andrey S Glotov; Ekaterina Y Zakharova; Oleg S Glotov
Journal:  Biomed Rep       Date:  2020-11-17

5.  Endoplasmic reticulum quality control of LDLR variants associated with familial hypercholesterolemia.

Authors:  Praseetha Kizhakkedath; Anne John; Buthaina K Al-Sawafi; Lihadh Al-Gazali; Bassam R Ali
Journal:  FEBS Open Bio       Date:  2019-10-23       Impact factor: 2.693

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.